Study of Blood Lactate Levels in Patients Treated With Antipsychotics

2014-08-27 03:13:07 | BioPortfolio


Blood lactate levels in patients receiving typical or atypical antipsychotics have not been described in the literature.

The goal of this study is to assess the dynamics of lactate levels in the blood from typical or atypical antipsychotics not confounded by prior antipsychotic treatments, the investigators conducted a prospective study of lactate levels in patients receiving antipsychotic medication. The investigators hypothesized that 6 months of treatment with haloperidol or olanzapine would result in a change in blood lactate levels and extrapyramidal side effects.


The aim of this study was to compare the blood lactate levels in patients receiving typical or atypical antipsychotics.

Subjects included sixty patients with psychotic disorder were assigned to treatment for 6 months with haloperidol (typical antipsychotic), N=30 or olanzapine (atypical antipsychotic), N=30. Blood lactate levels, other metabolic parameters, and scores on the extrapyramidal symptom rating scale (ESRS) were assessed.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Movement Disorders


Haloperidol or olanzapine


Split Clinical Hospital Center




University of Split

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:13:07-0400

Clinical Trials [741 Associated Clinical Trials listed on BioPortfolio]

Haloperidol vs Olanzapine for the Management of ICU Delirium

The purpose of this randomized clinical trial is to determine whether haloperidol is superior to olanzapine for the treatment of ICU acquired delirium. The hypothesis is that haloperidol ...

Oral Olanzapine Versus Haloperidol or Diazepam

The purpose of this study is to determine whether oral olanzapine is safer (fewer adverse events) and more effective (shorter time to sedation) than conventional haloperidol or diazepam wh...

IM Olanzapine Versus Haloperidol or Midazolam

The purpose of this study is to determine whether IM olanzapine is safer (fewer adverse events) and more effective (shorter time to sedation) than conventional haloperidol or midazolam whe...

Clozapine and Olanzapine Treatment of Aggression

This was a double-blind randomized study with three treatment arms: clozapine, olanzapine and haloperidol. We compared these three medications in the treatment of aggressive behavior over ...

Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia

The purpose of this study is to compare intramuscular Olanzapine and intramuscular Haloperidol in changing of agitation in patients with schizophrenia

PubMed Articles [6773 Associated PubMed Articles listed on BioPortfolio]

Clinical Presentation and Prognosis of Common Movement Disorders.

Great progress has been made in expanding our understanding of the natural history of movement disorders, leading to impressive advancements in their medical and surgical management. Movement disorder...

2018 message from the editor in chief-Movement Disorders journal at cruise speed.

Disruption of dopamine D1/D2 receptor complex is involved in the function of haloperidol in cardiac H9c2 cells.

Haloperidol is an antipsychotic agent and acts as dopamine D2 receptor (D2R) antagonist, as a prototypical ligand of sigma1 receptors (Sig1R) and it increases expression of type 1 IP3 receptors (IP3R1...

Crossing barriers: a multidisciplinary approach to children and adults with young-onset movement disorders.

Diagnosis of less common young-onset movement disorders is often challenging, requiring a broad spectrum of skills of clinicians regarding phenotyping, normal and abnormal development and the wide ran...

Long-acting olanzapine injection during pregnancy and breastfeeding: a case report.

We present one case of a woman treated with the intramuscular depot formulation of the atypical antipsychotic, olanzapine pamoate (ZypAdhera®), during pregnancy and breastfeeding. Data on olanzapine ...

Medical and Biotech [MESH] Definitions

One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.

Disorders of the centrally located thalamus, which integrates a wide range of cortical and subcortical information. Manifestations include sensory loss, MOVEMENT DISORDERS; ATAXIA, pain syndromes, visual disorders, a variety of neuropsychological conditions, and COMA. Relatively common etiologies include CEREBROVASCULAR DISORDERS; CRANIOCEREBRAL TRAUMA; BRAIN NEOPLASMS; BRAIN HYPOXIA; INTRACRANIAL HEMORRHAGES; and infectious processes.

A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in MENTAL RETARDATION and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)

An antidepressive agent that has also been used in the treatment of movement disorders. The mechanism of action is not well understood.

Excessive movement of muscles of the body as a whole, which may be associated with organic or psychological disorders.

More From BioPortfolio on "Study of Blood Lactate Levels in Patients Treated With Antipsychotics"

Quick Search


Relevant Topic

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Searches Linking to this Trial